Biognosys Company
Biognosys is a company that aims to enable the routine analysis of proteomes in research and clinical laboratories worldwide. They offer a unique next-generation solution for precise quantification of large proteomes in biological samples, which provides unprecedented depth and quality of protein expression data for more effective biomarker and drug-target discovery and validation. Biognosys is a spin-off from the leading proteomics lab of Prof. Ruedi Aebersold, ETH Zurich. They are a leading global proteomics company that offers next-generation proteomics solutions based on proprietary mass spectrometry technology.
Industry:
Gene Therapy
Estimated Revenue:
$1-$10 millionBiognosys's
Headquarters:
Zurich